First molecules discovered by next-generation artificial intelligence to be developed into drugs

IMAGE: This is the overview of Pharma AI drug discovery pipeline. Thursday, July 27, 2017, Baltimore, Md., Insilico Medicine ("Insilico"), a Baltimore-based leader in artificial intelligence ("AI") for drug discovery and biomarker development, is pleased to announce a multi-year drug development agreement with the biotechnology company Juvenescence AI Limited ("Juvenescence AI"). Juvenescence AI will develop the first compounds generated by Insilico's deep-learned drug discovery engines, which train over structural, functional, and phenotypic data in order to predict the biological activity of compounds. Insilico's platforms incorporate new AI techniques such as Generative Adversarial Networks in order to generate novel compounds with desired pharmacokinetic and pharmacodynamic properties. As part of the agreement, Juvenescence Limited ("Juvenescence"), the parent company of Juvenescence AI, made a direct investment into Insilico to further advance Insilico's drug discovery platform and develop a set of companion multi-modal disease biomarkers.